TR200200986T2 - C-aril glukozid SGLT2 önleyicileri. - Google Patents

C-aril glukozid SGLT2 önleyicileri.

Info

Publication number
TR200200986T2
TR200200986T2 TR2002/00986T TR200200986T TR200200986T2 TR 200200986 T2 TR200200986 T2 TR 200200986T2 TR 2002/00986 T TR2002/00986 T TR 2002/00986T TR 200200986 T TR200200986 T TR 200200986T TR 200200986 T2 TR200200986 T2 TR 200200986T2
Authority
TR
Turkey
Prior art keywords
sglt2 inhibitors
aryl glucoside
glucoside sglt2
sglt2 inhibitor
aryl
Prior art date
Application number
TR2002/00986T
Other languages
English (en)
Turkish (tr)
Inventor
Ellsworth Bruce
N. Washburn William
M. Sher Philip
Wu Gang
Meng Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200986(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200200986T2 publication Critical patent/TR200200986T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TR2002/00986T 1999-10-12 2000-10-02 C-aril glukozid SGLT2 önleyicileri. TR200200986T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15877399P 1999-10-12 1999-10-12
US19461500P 2000-04-05 2000-04-05

Publications (1)

Publication Number Publication Date
TR200200986T2 true TR200200986T2 (tr) 2002-07-22

Family

ID=26855382

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00986T TR200200986T2 (tr) 1999-10-12 2000-10-02 C-aril glukozid SGLT2 önleyicileri.

Country Status (32)

Country Link
US (1) US6414126B1 (OSRAM)
EP (1) EP1224195B1 (OSRAM)
JP (1) JP4365554B2 (OSRAM)
KR (1) KR100728085B1 (OSRAM)
CN (1) CN1284793C (OSRAM)
AR (1) AR026024A1 (OSRAM)
AT (1) ATE295848T1 (OSRAM)
AU (1) AU781009B2 (OSRAM)
BR (2) BRPI0014722B8 (OSRAM)
CA (1) CA2388818C (OSRAM)
CO (1) CO5251414A1 (OSRAM)
CZ (1) CZ304522B6 (OSRAM)
DE (1) DE60020259T2 (OSRAM)
EG (1) EG24515A (OSRAM)
ES (1) ES2240179T3 (OSRAM)
HK (1) HK1044541B (OSRAM)
HU (2) HU230727B1 (OSRAM)
IL (2) IL148806A0 (OSRAM)
IN (1) IN2007MU00019A (OSRAM)
MX (1) MX237254B (OSRAM)
MY (1) MY125405A (OSRAM)
NO (2) NO323698B1 (OSRAM)
NZ (1) NZ518029A (OSRAM)
PE (1) PE20011000A1 (OSRAM)
PH (1) PH12000002657B1 (OSRAM)
PL (1) PL204358B1 (OSRAM)
PT (1) PT1224195E (OSRAM)
RU (1) RU2262507C2 (OSRAM)
TR (1) TR200200986T2 (OSRAM)
TW (1) TWI254714B (OSRAM)
UY (1) UY26391A1 (OSRAM)
WO (1) WO2001027128A1 (OSRAM)

Families Citing this family (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
SK9292002A3 (en) * 1999-12-28 2002-10-08 Ajinomoto Kk Oral preparations for diabetes
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
DK1333887T3 (da) * 2000-10-30 2006-11-13 Ortho Mcneil Pharm Inc Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP2065044A1 (en) * 2001-04-04 2009-06-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
WO2003011880A1 (fr) * 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1461069A2 (en) * 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003075911A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20050215489A1 (en) * 2002-03-14 2005-09-29 Bayer Pharmaceuticals Corporation Methods of treating diabetes using pde 11a inhibitors
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
AU2003231517A1 (en) * 2002-04-26 2003-11-10 Ajinomoto Co., Inc. Preventive/remedy for diabetes
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
JP4530855B2 (ja) 2002-10-04 2010-08-25 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006516257A (ja) 2003-01-03 2006-06-29 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
PL1980560T3 (pl) 2003-03-14 2011-11-30 Astellas Pharma Inc Pochodne C-glikozydowe do leczenia cukrzycy
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
CA2524134C (en) * 2003-04-28 2017-07-04 Sankyo Company Limited Adiponectin production enhancer
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
RS20060320A (en) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EA011515B1 (ru) 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AU2004261664A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-O-glucosides
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1687410A4 (en) * 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
AU2004288831B2 (en) 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1581246B1 (en) * 2003-12-17 2013-01-16 Amylin Pharmaceuticals, LLC Compositions for the treatment and prevention of nephropathy
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
WO2005085265A1 (ja) * 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
CN1934103B (zh) * 2004-03-04 2011-06-01 橘生药品工业株式会社 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途
BRPI0508830B8 (pt) 2004-03-16 2021-05-25 Boehringer Ingelheim Int derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
JPWO2005095372A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
WO2005095429A1 (ja) * 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. フェノール誘導体、それを含有する医薬組成物及びその医薬用途
TW200602335A (en) * 2004-03-31 2006-01-16 Kissei Pharmaceutical Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
KR20070048188A (ko) * 2004-07-08 2007-05-08 아스텔라스세이야쿠 가부시키가이샤 아줄렌 유도체의 제조방법 및 이의 합성 중간체
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
WO2006009149A1 (ja) * 2004-07-21 2006-01-26 Kissei Pharmaceutical Co., Ltd. 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008508213A (ja) 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
MX2007003785A (es) * 2004-09-29 2007-07-12 Kissei Pharmaceutical Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
ZA200706022B (en) * 2005-01-28 2008-11-26 Chugai Pharmaceutical Co Ltd Spiroketal derivatives and use thereof as diabetic medicine
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP4496174B2 (ja) * 2005-01-31 2010-07-07 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
ATE421518T1 (de) * 2005-02-10 2009-02-15 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
JP5264183B2 (ja) * 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
WO2006099245A1 (en) * 2005-03-11 2006-09-21 Elixir Pharmaceuticals, Inc. Sirt inhibitors that bind to nad
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
CA2605245A1 (en) * 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
JP5128474B2 (ja) * 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
JP5175191B2 (ja) * 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
KR20080053369A (ko) 2005-09-08 2008-06-12 베링거 인겔하임 인터내셔날 게엠베하 1-클로로-4-(β-Ｄ-글루코피라노스-1-일)-2-(4-에티닐-벤질)-벤젠의 결정형, 이의 제조 방법 및 약제 제조를 위한이의 용도
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
JP2009531291A (ja) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7973012B2 (en) * 2006-05-19 2011-07-05 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JP5152519B2 (ja) 2006-06-29 2013-02-27 大正製薬株式会社 Ｃ−フェニル１−チオグルシト−ル化合物
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008034859A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20100093744A1 (en) 2006-10-13 2010-04-15 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ATE528300T1 (de) 2006-12-06 2011-10-15 Glaxosmithkline Llc Bizyklische verbindungen und ihre verwendung als antidiabetika
KR101100072B1 (ko) 2006-12-21 2011-12-29 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체의 제조방법 및 이의 합성 중간체
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
EP2125768A1 (en) * 2007-02-21 2009-12-02 Boehringer Ingelheim International GmbH Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
RU2492175C2 (ru) * 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
WO2008144346A2 (en) * 2007-05-18 2008-11-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for their preparation
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8383609B2 (en) 2007-07-05 2013-02-26 Centre National De La Recherche Scientifique Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
CN103254119B (zh) * 2007-07-10 2016-07-06 莱西肯医药有限公司 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
PL2183263T3 (pl) 2007-07-26 2012-03-30 Lexicon Pharmaceuticals Inc Sposoby i związki przydatne do otrzymywania inhibitorów kotransportera 2 sodowo-glukozowego
JP2010534722A (ja) * 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
AR068016A1 (es) * 2007-08-23 2009-10-28 Theracos Inc Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt
ME03072B (me) 2007-09-10 2019-01-20 Janssen Pharmaceutica Nv Postupak za dobijanje jedinjenja која su korisna као inhibiтori sgl т
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
RU2509773C2 (ru) * 2008-07-15 2014-03-20 Теракос, Инк. Дейтерированные бензилбензольные производные и способы применения
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
NZ604897A (en) 2008-08-22 2014-03-28 Theracos Sub Llc Processes for the preparation of sglt2 inhibitors
CA2733795C (en) * 2008-08-28 2013-12-31 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RU2411936C2 (ru) * 2009-01-11 2011-02-20 Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом
HUE066463T2 (hu) * 2009-02-13 2024-08-28 Boehringer Ingelheim Int Gyógyszerkészítmény, gyógyszeradagolási forma, eljárás ezek elõállítására, kezelési módszerek és alkalmazásuk
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
ES2797503T3 (es) 2009-02-13 2020-12-02 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de SGLT2, un inhibidor de DPP-IV y opcionalmente un agente antidiabético adicional y sus usos
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8685934B2 (en) * 2009-05-27 2014-04-01 Bristol-Myers Squibb Company Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
AU2010303124B2 (en) 2009-09-30 2014-01-23 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
MX2012002942A (es) 2009-09-30 2012-04-11 Boehringer Ingelheim Int Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
LT2488515T (lt) 2009-10-14 2017-03-10 Janssen Pharmaceutica Nv Junginių, naudotinų kaip sglt2 inhibitorių, paruošimo būdas
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2491050A2 (en) 2009-10-20 2012-08-29 Novartis AG Glycoside derivative and uses thereof
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
PT2498759T (pt) 2009-11-13 2018-11-15 Astrazeneca Uk Ltd Formulações de comprimidos de libertação imediata
AR079438A1 (es) * 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
ME02531B (me) 2010-05-11 2017-02-20 Janssen Pharmaceutica Nv FARMACEUTSKE FORMULACilE KOJE OBUHVATAJU DERIVATIVE 1 - (BE TA- D- GLUKOPIRANOZ IL)-2- TIENILMETILBENZENA KAO SGLT INHIBITORE
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
KR20130137624A (ko) 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru) 2011-02-01 2017-01-10 Бристол-Майерс Сквибб Компани Фармацевтические композиции, содержащие аминосоединение
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102643256B (zh) 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102675378A (zh) * 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
EA201391524A1 (ru) 2011-04-14 2014-04-30 Новартис Аг Производные гликозида и их применение
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
TR201903445T4 (tr) * 2011-06-01 2019-03-21 Green Cross Corp Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇
BR112013031032A2 (pt) 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
AR086922A1 (es) * 2011-06-13 2014-01-29 Panacea Biotec Ltd Derivados de 3,4,5-trihidroxi-6-(hidroximetil)tetrahidro-2h-pirano utiles para el tratamiento de diabetes y dislipidemias, composiciones farmaceuticas que los contienen y metodo para prepararlos
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
EP2725031B1 (en) 2011-06-25 2016-08-03 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8710049B2 (en) 2011-07-18 2014-04-29 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013178064A1 (zh) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
CA2883118A1 (en) * 2012-08-30 2014-03-06 Taisho Pharmaceutical Co., Ltd. Combinations of sglt 2 inhibitors and antihypertensive drugs
WO2014039412A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9573959B2 (en) 2013-03-14 2017-02-21 Msd International Gmbh Methods for preparing SGLT2 inhibitors
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治療胃腸道病症的組成物
CN104059042B (zh) * 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20220365T1 (hr) 2013-04-18 2022-05-13 Boehringer Ingelheim International Gmbh Farmaceutski pripravak, postupci za liječenje i njegove uporabe
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015032272A1 (zh) * 2013-09-09 2015-03-12 江苏豪森药业股份有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
JP6450769B2 (ja) 2013-09-27 2019-01-09 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． グルコピラノシル誘導体及びその医薬品における使用
CN105611920B (zh) * 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
SI3862003T1 (sl) 2013-12-17 2024-02-29 Boehringer Ingelheim Vetmedica Gmbh Inhibitor SGLT-2 za uporabo pri zdravljenju metabolične motnje pri mačjih živalih
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
EP2891654B1 (en) 2014-01-03 2016-06-22 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
DK3485890T3 (da) * 2014-01-23 2023-08-21 Boehringer Ingelheim Vetmedica Gmbh Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr
WO2015132803A2 (en) * 2014-03-06 2015-09-11 Msn Laboratories Private Limited Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof
EP4454653A3 (en) 2014-04-01 2025-01-22 Boehringer Ingelheim Vetmedica GmbH Treatment of pituitary pars intermedia dysfunction in equine animals
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
TW201623321A (zh) 2014-05-13 2016-07-01 韓美藥品股份有限公司 雙環衍生物及包含其之藥學組成物
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105085494B (zh) * 2014-05-22 2019-07-02 中国医学科学院药物研究所 钠糖共转运体2抑制剂、其制法和其药物组合物与用途
CA2961148A1 (en) 2014-09-25 2016-03-31 Astrazeneca Ab Use of a combination of an omega-3 fatty acid and an sglt-2 inhibitor for the treatment of non-alcoholic liver disease
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
EP3256482B1 (en) * 2015-02-09 2019-11-27 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
FI3341024T3 (fi) 2015-08-27 2024-12-18 Boehringer Ingelheim Vetmedica Gmbh Sglt-2-estäjiä käsittäviä nestemäisiä farmaseuttisia koostumuksia
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US20170106009A1 (en) 2015-10-15 2017-04-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
KR102004488B1 (ko) 2015-12-11 2019-07-26 동아에스티 주식회사 다파글리플로진의 신규 용매화물 및 이의 제조방법
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
NZ743987A (en) 2016-01-04 2019-10-25 Je Il Pharmaceutical Co Ltd C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017221211A1 (en) * 2016-06-24 2017-12-28 Biocon Limited Process for the preparation of dapagliflozin and its solvate thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018073154A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
KR101943382B1 (ko) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
KR20200022257A (ko) * 2018-08-22 2020-03-03 동아에스티 주식회사 Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
HUE064995T2 (hu) 2018-10-29 2024-04-28 Boehringer Ingelheim Int Piridinil-szulfonamid-származékok, gyógyszerkészítmények és azok felhasználása
CN111471032B (zh) * 2019-01-24 2023-08-01 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111471040B (zh) * 2019-01-24 2023-06-02 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
WO2020151621A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及医药用途
CN111471031B (zh) * 2019-01-24 2023-05-16 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
CN111840271B (zh) * 2019-04-25 2024-05-14 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物新用途
CA3079175A1 (en) 2019-08-30 2021-02-28 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
MX2022006490A (es) 2019-11-28 2022-07-04 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.
RS65877B1 (sr) 2020-02-07 2024-09-30 Gasherbrum Bio Inc Heterociklični agonisti glp-1
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
BR112022017189A2 (pt) 2020-03-06 2022-10-18 Vertex Pharma Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
US20230201174A1 (en) 2020-04-22 2023-06-29 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20230165856A1 (en) 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
EP4161912A1 (en) 2020-06-05 2023-04-12 KRKA, d.d., Novo mesto Preparation of highly pure amorphous dapagliflozin
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
CN114539231B (zh) * 2020-11-19 2023-11-21 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
KR20220091233A (ko) 2020-12-23 2022-06-30 (주)국전약품 다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2022251165A1 (en) 2021-04-01 2023-11-09 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
EP4376829A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
JP2025503136A (ja) 2022-01-26 2025-01-30 アストラゼネカ・アクチエボラーグ 前糖尿病の治療又は２型糖尿病の発症リスクを低減する際に使用するためのダパグリフロジン
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024033288A1 (en) * 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Salicin derivatives as inhibitors of sglt2
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
US20240390332A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
CZ290072B6 (cs) 1995-06-29 2002-05-15 Texas Biotechnology Corporation Di- a trivalentní malé molekuly selektinových inhibitorů
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
ATE216704T1 (de) 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
AU6024998A (en) * 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
EP1213296B1 (en) * 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof

Also Published As

Publication number Publication date
AU781009B2 (en) 2005-04-28
DE60020259T2 (de) 2006-01-19
CN1407990A (zh) 2003-04-02
CZ304522B6 (cs) 2014-06-18
PL355018A1 (en) 2004-03-22
PE20011000A1 (es) 2001-11-25
AU7848300A (en) 2001-04-23
DE60020259D1 (de) 2005-06-23
NO20070149L (no) 2002-06-10
PL204358B1 (pl) 2010-01-29
HUP0300393A2 (hu) 2003-06-28
CZ20021285A3 (cs) 2003-02-12
US6414126B1 (en) 2002-07-02
CA2388818C (en) 2012-07-03
EP1224195B1 (en) 2005-05-18
HUP0300393A3 (en) 2003-09-29
MY125405A (en) 2006-07-31
CN1284793C (zh) 2006-11-15
MX237254B (es) 2006-05-26
JP4365554B2 (ja) 2009-11-18
BR0014722A (pt) 2003-02-25
EP1224195A1 (en) 2002-07-24
EG24515A (en) 2009-08-19
NO20021721L (no) 2002-06-10
JP2003511458A (ja) 2003-03-25
HK1044541B (en) 2005-11-11
CA2388818A1 (en) 2001-04-19
KR20020063876A (ko) 2002-08-05
IL148806A0 (en) 2002-09-12
IN2007MU00019A (OSRAM) 2007-08-03
ATE295848T1 (de) 2005-06-15
NO323698B1 (no) 2007-06-25
HU229446B1 (en) 2013-12-30
UY26391A1 (es) 2001-05-31
PT1224195E (pt) 2005-07-29
WO2001027128A1 (en) 2001-04-19
ES2240179T3 (es) 2005-10-16
AR026024A1 (es) 2002-12-26
CO5251414A1 (es) 2003-02-28
BRPI0014722B1 (pt) 2019-09-24
PH12000002657B1 (en) 2006-02-21
NO332798B1 (no) 2013-01-14
IL148806A (en) 2010-06-16
NO20021721D0 (no) 2002-04-11
RU2002109477A (ru) 2004-01-20
RU2262507C2 (ru) 2005-10-20
HU230727B1 (hu) 2017-12-28
HK1044541A1 (en) 2002-10-25
TWI254714B (en) 2006-05-11
BRPI0014722B8 (pt) 2021-05-25
MXPA02003625A (es) 2002-10-23
KR100728085B1 (ko) 2007-06-14
NZ518029A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
TR200200986T2 (tr) C-aril glukozid SGLT2 önleyicileri.
MY142499A (en) C-aryl glucoside sglt2 inhibitors and method
NO20024642D0 (no) O-aryl glukosid SGLT2 inhibitorer og fremgangsmåte
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
GB9801690D0 (en) Therapeutic agents
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
DK0799209T3 (da) Sulfonamider
WO2001060416A3 (en) Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
MXPA04004548A (es) Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa.
BG106104A (en) Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation
CA2294171A1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
FI964772A0 (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
IS4725A (is) Afleiður amidíns og ísóþíóþvagefnis er hindra nítrítoxíðsyntasa
EP1772452A3 (en) Matrix metalloproteinase inhibitors and uses thereof
NO940777D0 (no) Anvendelse av et pregnanderivat
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
AU5390900A (en) Potassium channel blocking agents
AP2000001760A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
TR199801133T2 (xx) Tip II diyabetin tedavisi veya �nlenmesi i�in nitrik oksit (NO) sentaz inhibit�r�
BR9508521A (pt) Inibição da biossintese de leucotrienos com derivados de uréia